<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542968</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01482-51</org_study_id>
    <nct_id>NCT03542968</nct_id>
  </id_info>
  <brief_title>Imaging by 4 DFlow in Patients With Tetralogy of Fallot</brief_title>
  <acronym>4DFlowFallot</acronym>
  <official_title>Imaging by 4 DFlow in Patients With Tetralogy of Fallot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Chirurgical Marie Lannelongue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Chirurgical Marie Lannelongue</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventionnal cadiac magnetic resonance (CMR) is the reference to assess changes in right
      heart flow and pulmonary artery hemodynamics in patients with repaired Tetralogy of Fallot.

      4D Flow CMR Imaging is a new imaging modality able to assess all of these parameters faster
      (8 min vs 30 min) and more comfortably.

      The aim of this study is to compare conventionnal CMR and 4D Flow CMR for the assessment of
      these parameters (ventricular volume, ventricular systolic function, and regurgitation of the
      pulmonary pathway).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital heart disease, or corrected heart disease requires regular, specialized follow-up
      throughout the life of these patients. Among the recommended examinations, cardiac MRI is the
      reference for functionnal ventricles assessment (volume/systolic function), particularly for
      the right ventricle.

      Among these pathologies, the tetralogy of Fallot is indicative of the increasing importance
      of cardiac MRI. In this disease, strong parameters has been identifies for the follow to
      prevent right ventricle dysfunction and ventricular arrhythmias. They rely on right ventricle
      volumes and on the pulmonary artery regurgitation, both using cardiac MRI.

      However, this imaging modality imposes constraints such as a long acquisition times (30 to 40
      min) or the need to hold apneas, which may render the procedure uncomfortable, even more in
      the case of very young patients.

      The idea of exploring a new imaging modality is therefore based on the willingness to offer a
      faster and more comfortable examination. 4D Flow MRI could enable conventionnal parameters,
      detection of both normal and abnormal right heart flow patterns, and may allow comprehensive
      analysis of post-surgically altered geometries and hemodynamics.

      4D Flow MRI cardiac imaging is :

        -  A single and faster acquisition (8 to 15 minutes) that cardiac MRI.

        -  A free breathing acquisition Imaging modality.

        -  A quite-isotropic assessment.

        -  A technically simple exam (a single sequence requiring low competence).

        -  And offers unlimited post processing.

      The investigators hypothesize that 4D MRI is non-inferior to 2D MRI in patients with
      corrected tetralogy of Fallot, for the evaluation of conventional cardiac evaluation
      parameters: ventricular volume, ventricular systolic function, and regurgitation of the
      pulmonary pathway.

      The investigators hypothesize that 4D MRI is superior to 2D MRI in patients with corrected
      tetralogy of Fallot, as ti allows to identifying new predictors of ventricular dysfunction
      such as intravenous extracardiac turbulent / laminar flow character, preferential
      orientation, flow distribution and trans-tricuspid diastolic flow.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">April 11, 2020</completion_date>
  <primary_completion_date type="Actual">October 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the pulmonary artery regurgitation using 2D MRI and 4D Flow MRI.</measure>
    <time_frame>20 min</time_frame>
    <description>Assessment of the pulmonary artery regurgitation using 2D MRI and 4D Flow MRI : regurgitation volume (ml) and regurgitation fraction (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the evaluation of right ventricle volumes using 2D MRI and 4D Flow MRI.</measure>
    <time_frame>20 min</time_frame>
    <description>Assessment of the end-diastolic and end-systolic right ventricle volumes using 2D MRI and 4D Flow MRI (ml).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>4D magnetic resonance imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2D magnetic resonance imaging</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Acquisition 4D Flow magnetic resonance Imaging-8 minutes</description>
    <arm_group_label>2D magnetic resonance imaging</arm_group_label>
    <arm_group_label>4D magnetic resonance imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - children from the age of 10 and above without any upper age limit;

          -  giving their informed consent for the study;

          -  with a corrected tetralogy of Fallot;

          -  sent for a follow-up imaging examination with endomyocardial fibrosis screening;

        Exclusion Criteria:

          -  - pregnant woman;

          -  children &lt;10 years old;

          -  All contraindications inherent to MRI: (claustrophobia, ferromagnetic intracorporeal
             foreign bodies)

          -  Contraindication to contrast media injection (Gadolinium)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Antoine ISORNI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Marie Lannelongue</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaf Mercier, Professor</last_name>
    <phone>+33140948695</phone>
    <email>o.mercier@hml.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc antoine ISORNI</last_name>
      <phone>+33140948554</phone>
      <email>ma-isorni@hml.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital heart disease</keyword>
  <keyword>Tetralogy of Fallot</keyword>
  <keyword>Imaging by 4D Flow,</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Prevention of ventricular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

